Dr Vix Manning and Dr Charlotte Woodward examine how medically supervised FMD protocols address post-GLP-1 metabolic instability
The landscape of metabolic medicine has been revolutionised by GLP-1 and GIP receptor agonists, with remarkable success in achieving rapid weight loss and glycaemic control. However, a growing clinical challenge is emerging: what happens when patients experience metabolic ‘wobbles’ during or after these treatments? In the UK, the metabolic health crisis continues to escalate. According to NHS England data from 2024, 29% of adults are classified as obese, with 64% overweight or obese.¹
Type 2 diabetes prevalence reached 7% of the population by March 2024,² while cases among under-40s have risen alarmingly, with almost 168,000 now affected an increase of over 47,000 since 2016-17.³ These statistics underscore the urgent need for innovative therapeutic interventions addressing metabolic dysfunction at its cellular foundation.
A Fasting Mimicking Diet (FMD) offers a scientifically validated intervention originally developed for type 2 diabetes management, but now showing particular promise for patients experiencing…
